Fluidic Analytics is a spin-out from the University of Cambridge developing tools for the characterisation of proteins. The company’s microfluidic diffusional sizing (MDS) technology can analyse proteins in solution and in complex backgrounds, allowing users to characterise, quantify and distinguish protein interactions of all kinds. Fluidic’s vision is to provide real-time updates about a patient’s health status, including drug responses, early stages of disease, or the development of allergies.
IQ Capital led each of Fluidic’s seed stage rounds in 2014-2016, and has continued to invest at Series A in 2018 through Series C in 2020.
"The cross disciplinary technical exposure that IQ has is incredibly valuable to all of their portfolio companies."